Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting

INTRODUCTION: The superior efficacy and safety of semaglutide once-weekly (QW), compared with dulaglutide, liraglutide, or exenatide QW, have been demonstrated in the SUSTAIN trials. This study assessed treatment persistence and adherence to semaglutide QW versus dulaglutide, liraglutide, or exenati...

Descripción completa

Detalles Bibliográficos
Autores principales: Uzoigwe, Chioma, Liang, Yuanjie, Whitmire, Sarah, Paprocki, Yurek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099966/
https://www.ncbi.nlm.nih.gov/pubmed/33837922
http://dx.doi.org/10.1007/s13300-021-01053-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099966/
https://www.ncbi.nlm.nih.gov/pubmed/33837922
http://dx.doi.org/10.1007/s13300-021-01053-7

Ejemplares similares